• Sevoflurane- Safety in Long-term Sedation Procedures

  NCT01802255

  WithdrawnInterventionalPhase 3Updated Aug 24, 2021
• Effect of Inhalation Sedation Compared With Propofol on the Sepsis-related Acute Respiratory Distress Syndrome Course

  NCT04014218

  Unknown statusInterventionalPhase 4Updated Jul 10, 2019
• Sevoflurane in COVID-19 ARDS (SevCov)

  NCT04355962

  CompletedInterventionalPhase 3Updated Jul 19, 2021
• Comparison of Extubation Delay After Prolonged Sedation

  NCT04710914

  TerminatedInterventionalPhase 4Updated Feb 10, 2026
• SEvoflurane for Sedation in ARds

  NCT04235608

  CompletedInterventionalPhase 3Updated Apr 21, 2026
• Sevoflurane in Subarachnoidal Haemorrhage

  NCT02946437

  WithdrawnInterventionalPhase 2Updated Jun 2, 2020

ClinicalTrials.gov ID

NCT03643367

Lead Sponsor

University of ZurichOTHER

Overall Status

Not yet recruiting

Study Type

Interventional

Phase

Phase 2

Enrollment

153Estimated

Last Update Posted

Apr 1, 2025Actual

Start Date

Jan 2026Estimated

Primary Completion Date

Feb 2027Estimated

Completion Date

Nov 2027Estimated

Official Title

Sevoflurane Sedation: A Potentially Promising Immunomodulation in Patients With Septic Shock

Brief Summary

Recent in vivo studies from others as well as the investigators group demonstrated that volatile anesthetics immunomodulate sepsis and improve outcome. Also, several clinical trials have convincingly shown that application of a volatile anesthetic provides protection in patients undergoing major surgery.

Patients with sepsis are intubated and ventilated and therefore need sedation. So far, most ICU centers use intravenously applied sedatives in these patients. In the proposed study, we will switch sedation from an intravenous to a volatile anesthetic for a short period of time to explore if sepsis markers improve within the following 120 hours upon sevoflurane conditioning.

Detailed Description

This randomized controlled trial (RCT) will be conducted over a period of 48 months, to investigate if volatile anesthetics have a positive effect on the prognostic sepsis marker IL-6. All patients with septic shock are intubated, ventilated and sedated with an intravenous anesthetic. In this study, eligible patients diagnosed with septic shock will be randomized 1:1 to the 'volatile group' with interruption of the propofol infusion, followed by a 4-hour sedation with the volatile anesthetic sevoflurane, or a continuous intravenous sedation ('intravenous' =control group). In both groups, 'intravenous' and 'volatile', the inflammatory markers as well as clinical parameters will be determined. The investigators will explore if there is a difference between the course of sepsis markers of the two groups within 5 days after intervention in favor of the volatile group.

• Shock, Septic

• Sevoflurane
• Control Group

Ages Eligible for Study

Adult (18-64)Older Adult (65+)

Sexes Eligible for Study

All

Accepts Healthy Volunteers

No

Eligibility Criteria

Inclusion Criteria:

• Male and female patients, age 18 to 80 years
• Intensive care Unit (ICU) patients with septic shock (despite fluid resuscitation vasopressors needed to maintain mean arterial pressure ≥65 millimeter of mercury (mmHg), and serum lactate >2mmol/l even with fluid application)
• Treatment of septic shock on ICU with vasopressors not longer than 12 hours
• Sedation and mechanical ventilation on ICU
• Female patients of childbearing potential with negative pregnancy test
• Informed Consent as documented by signature

Exclusion Criteria:

• Previous surgery and/or anesthesia (within last 7 days)
• Application of nitric oxide (NO)
• Suspected or known intolerance by history to volatile anesthetics (malignant hyperthermia)
• Immunosuppressive agents
• Systemic corticosteroids in the phase before hospitalization (> 10mg/d prednisone)
• Significant concomitant disease (acute cerebral vascular event, acute coronary syndrome, decompensated heart failure, acute pulmonary edema, major cardiac arrhythmia, seizure, burn, chronic kidney disease, end stage liver failure, neuromuscular disease)
• AIDS
• Autoimmune disease
• Organ transplant
• Subject with active malignancy receiving
• chemotherapy or radiation treatment within last 60 days
• Hepatitis B/C virus infection
• Anti-tumor necrosis factor (TNF) therapy
• Pregnancy and/or Breast feeding
• Use of cytokine absorber
• Enrollment in any other clinical trial during the course of this trial, 30 days prior to its beginning or 30 days after its completion

Primary Purpose

Treatment

Allocation

Randomized

Interventional Model

Parallel Assignment

Masking

Double

Lead Sponsor

University of ZurichOTHER

Collaborators

Kantonsspital MünsterlingenOTHER

Triemli HospitalOTHER

Waid City Hospital, ZurichOTHER

patricia.fodor@triemli.zuerich.ch+41444165202

martin.schlaepfer@usz.ch+41442551111

christian.giambarba@waid.zuerich.ch+41443662021